Docstoc

Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

Document Sample
Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018 Powered By Docstoc
					Transparency Market Research



Liver Diseases                                                           Buy Now
Therapeutics Market -
                                                                         Request Sample
Global Industry Analysis,
Size, Share, Trends And                                              Published Date: Jan 2013
Forecast, 2012 – 2018
 Single User License: US $ 4595
                                                                               112 Pages Report
 Multi User License: US $ 7595

 Corporate User License: US $ 10595



     REPORT DESCRIPTION

     Liver Diseases Therapeutics Market - Global Industry Analysis, Size, Share, Trends
     And Forecast, 2012 – 2018

     This report covers the performance of the various drugs class segment used in liver disease
     therapeutics in terms of their revenue. The global market for liver diseases therapeutics is
     classified into seven drug class segments namely, anti-viral drugs, vaccines,
     immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and
     chemotherapy with their estimated and forecasted market size from 2012 to 2018, along
     with their compound annual growth rate.

     This report also covers an in-depth competitive analysis for the market, taking into
     consideration some of the major market players. The market players considered are: Abbott
     Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb,
     Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company
     overview, financial overview, product portfolio and recent developments is also provided in
     the report.
Browse Report: Liver Diseases Therapeutics Market

We have used secondary research for deriving our market numbers for each segment of the
research report and further validated our analysis with C-level executives of major
companies operating in liver diseases therapeutics market through the means of primary
research to finally come up with our results. This research is specially designed to estimate
and analyze the performance of liver diseases therapeutics in a global scenario. This
research provides in-depth analysis of liver diseases therapeutics market sales, trend
analysis by segments.



TABLE OF CONTENTS

CHAPTER 1 PREFACE

1.1 REPORT DESCRIPTION

1.2 RESEARCH METHODOLOGY



CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW

3.1 INTRODUCTION

3.2 MARKET SIZE

3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY
DRUG CLASS, 2011 & 2018

3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS

    3.4.1 DRIVERS

           3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and
liver cancer

          3.4.1.2 Increasing global prevalence of liver diseases

          3.4.1.3 High unmet needs exist in the liver cancer therapeutics

          3.4.1.4 Increased vaccination in emerging economies

    3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS

    3.4.3 RESTRAINTS

          3.4.3.1 Side-effects and risks
            3.4.3.2 FDA approvals and other government regulations

            3.4.3.3 Availability of alternate treatment procedures

    3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS

    3.4.5 OPPORTUNITIES

            3.4.5.1 Strong pipeline drugs

            3.4.5.2 Emerging economies in Asia, Latin America and Eastern European
countries

            3.4.5.3 Consolidation opportunities in the healthcare industry

3.5 PORTER’S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET

    3.5.1 BARGAINING POWER OF SUPPLIERS

    3.5.2 BARGAINING POWER OF BUYERS

    3.5.3 THREAT OF NEW ENTRANTS

    3.5.4 THREAT OF SUBSTITUTES

    3.5.5 COMPETITIVE RIVALRY

CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS

4.1 ALCOHOL INDUCED LIVER DISEASE

    4.1.1 OVERVIEW

    4.1.2 EPIDEMIOLOGY

    4.1.3 ETIOLOGY

    4.1.4 SYMPTOMS

    4.1.5 PATHOPHYSIOLOGY

    4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS

            4.1.6.1 Anabolic Steroids

            4.1.6.2 Alcohol Abuse Drugs

4.2 AUTOIMMUNE LIVER DISORDER

    4.2.1 AUTOIMMUNE HEPATITIS (AIH)

Browse Report: http://www.transparencymarketresearch.com/liver-diseases-
therapeutics.html
         4.2.1.1 OVERVIEW

         4.2.1.2 EPIDEMIOLOGY

         4.2.1.3 ETIOLOGY

         4.2.1.4 SYMPTOMS

         4.2.1.5 PATHOPHYSIOLOGY

         4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS

                4.2.1.6.1 Antimetabolites

                4.2.1.6.2 Corticosteroids

4.3 HEPATOCELLULAR CARCINOMA

    4.3.1 OVERVIEW

    4.3.2 EPIDEMIOLOGY

    4.3.3 ETIOLOGY

    4.3.4 SYMPTOMS

    4.3.5 PATHOPHYSIOLOGY

    4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS

         4.3.6.1 Chemotherapy

         4.3.6.2 Targeted Therapy

4.4 NON-ALCOHOLIC FATTY LIVER DISEASE

    4.4.1 OVERVIEW

    4.4.2 EPIDEMIOLOGY

    4.4.3 ETIOLOGY

    4.4.4 SYMPTOMS

    4.4.5 PATHOPHYSIOLOGY

    4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS

         4.4.6.1 Gallstone solubilising drugs

4.5 VIRAL/HEPATITIS LIVER DISORDER

    4.5.1 HEPATITIS A
     Browse Report: http://www.transparencymarketresearch.com/liver-
diseases-therapeutics.html



        4.5.1.1 OVERVIEW

        4.5.1.2 EPIDEMIOLOGY

        4.5.1.3 ETIOLOGY

        4.5.1.4 SYMPTOMS

        4.5.1.5 PATHOPHYSIOLOGY

        4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS

               4.5.1.6.1 Vaccines

               4.5.1.6.2 Immunoglobulins

   4.5.2 HEPATITIS B

        4.5.2.1 OVERVIEW

        4.5.2.2 EPIDEMIOLOGY

        4.5.2.3 ETIOLOGY

        4.5.2.4 SYMPTOMS

        4.5.2.5 PATHOPHYSIOLOGY

        4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS

               4.5.2.6.1 Antiviral drugs

               4.5.2.6.2 Immunoglobulins

               4.5.2.6.3 Vaccines

   4.5.3 HEPATITIS C

        4.5.3.1 OVERVIEW

        4.5.3.2 EPIDEMIOLOGY

        4.5.3.3 ETIOLOGY

        4.5.3.4 SYMPTOMS

        4.5.3.5 PATHOPHYSIOLOGY
         4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS

                4.5.3.6.1 Antiviral drugs

    4.5.4 HEPATITIS D

         4.5.4.1 OVERVIEW

         4.5.4.2 EPIDEMIOLOGY

         4.5.4.3 ETIOLOGY

         4.5.4.4 SYMPTOMS

         4.5.4.5 PATHOPHYSIOLOGY

         4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS

    4.5.5 HEPATITIS E

         4.5.5.1 OVERVIEW

         4.5.5.2 EPIDEMIOLOGY

         4.5.5.3 ETIOLOGY

         4.5.5.4 SYMPTOMS

         4.5.5.5 PATHOPHYSIOLOGY

         4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONS



CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS

5.1 IMMUNOSUPPRESSANTS

    5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS,
2010 – 2018 (USD MILLION)

5.2 CHEMOTHERAPY DRUGS

    5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS,
2010 – 2018 (USD MILLION)

5.3 TARGETED THERAPY DRUGS

    5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010
– 2018 (USD MILLION)

5.4 VACCINES
    5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018
(USD MILLION)

5.5 ANTI-VIRAL DRUGS

    5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010
– 2018 (USD MILLION)

5.6 IMMUNOGLOBULINS

    5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010
– 2018 (USD MILLION)

5.7 CORTICOSTERIODS

    5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010
– 2018 (USD MILLION)



CHAPTER 6 COMPETITIVE LANDSCAPE

6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG
CLASS

    6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR
LIVER DISEASES

    6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES

    6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER
DISEASES

    6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES

    6.1.5 NEW ENTRANTS (PHASE III)

    6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS

        6.1.6.1 Investments in R&D and clinical studies

        6.1.6.2 Entering the emerging economies

        6.1.6.3 Investing in different segments of the market

    6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS

    6.1.8 AGREEMENTS AND COLLABORATIONS
Browse Report: http://www.transparencymarketresearch.com/liver-diseases-
therapeutics.html



CHAPTER 7 RECOMMENDATIONS

7.1 MARKET STRATEGY FOR SUCCESS

7.2 BARRIERS TO BE CONSIDERED



CHAPTER 8 COMPANY PROFILES

8.1 ABBOTT LABORATORIES

    8.1.1 COMPANY OVERVIEW

    8.1.2 FINANCIAL OVERVIEW

    8.1.3 BUSINESS STRATEGIES

        8.1.3.1 Significant R&D investments for new products development

        8.1.3.2 Investing in emerging markets

        8.1.3.3 Conducting clinical trials

    8.1.4 PRODUCT PORTFOLIO

    8.1.5 RECENT DEVELOPMENTS

8.2 ASTELLAS PHARMA INC.

    8.2.1 COMPANY OVERVIEW

    8.2.2 FINANCIAL OVERVIEW

    8.2.3 BUSINESS STRATEGIES

        8.2.3.1 Investing in emerging economies

        8.2.3.2 Investing in research and development

    8.2.4 PRODUCT PORTFOLIO

    8.2.5 RECENT DEVELOPMENTS

8.3 BRISTOL-MYERS SQUIBB

    8.3.1 COMPANY OVERVIEW
    8.3.2 FINANCIAL OVERVIEW

    8.3.3 BUSINESS STRATEGIES

        8.3.3.1 Mergers, acquisitiosn and strategic development

        8.3.3.2 Investing in research and development

    8.3.4 PRODUCT PORTFOLIO

    8.3.5 RECENT DEVELOPMENTS

8.4 GILEAD SCIENCES

    8.4.1 COMPANY OVERVIEW

    8.4.2 FINANCIAL OVERVIEW

    8.4.3 BUSINESS STRATEGIES

        8.4.3.1 Innovative new products

        8.4.3.2 Investing in research and development

    8.4.4 PRODUCT PORTFOLIO

    8.4.5 RECENT DEVELOPMENTS

8.5 GLAXOSMITHKLINE PLC

    8.5.1 COMPANY OVERVIEW

    8.5.2 FINANCIAL OVERVIEW

    8.5.3 BUSINESS STRATEGIES

        8.5.3.1 Research and development investments

        8.5.3.2 Delivering new products

    8.5.4 PRODUCT PORTFOLIO

    8.5.5 RECENT DEVELOPMENTS

8.6 F. HOFFMANN-LA ROCHE LTD

    8.6.1 COMPANY OVERVIEW

    8.6.2 FINANCIAL OVERVIEW

    8.6.3 BUSINESS STRATEGIES

        8.6.3.1 Strategic alliance initiative
         8.6.3.2 Investing in research and development

    8.6.4 PRODUCT PORTFOLIO

    8.6.5 RECENT DEVELOPMENTS

8.7 MERCK & CO. INC

    8.7.1 COMPANY OVERVIEW

    8.7.2 FINANCIAL OVERVIEW

    8.7.3 BUSINESS STRATEGIES

         8.7.3.1 R&D initiatives

         8.7.3.2 Strategic alliance

         8.7.3.3 Corporate social responsibility and awareness

    8.7.4 PRODUCT PORTFOLIO

    8.7.5 RECENT DEVELOPMENTS

8.8 NOVARTIS AG

    8.8.1 COMPANY OVERVIEW

    8.8.2 FINANCIAL OVERVIEW

    8.8.3 BUSINESS STRATEGIES

         8.8.3.1 Strategic alliance

         8.8.3.2 Investing in research and development

    8.8.4 PRODUCT PORTFOLIO

    8.8.5 RECENT DEVELOPMENTS

8.9 SANOFI S.A

    8.9.1 COMPANY OVERVIEW

    8.9.2 FINANCIAL OVERVIEW

    8.9.3 BUSINESS STRATEGIES

         8.9.3.1 Business Diversification

         8.9.3.2 Research and development initiative

    8.9.4 PRODUCT PORTFOLIO
    8.9.5 RECENT DEVELOPMENTS

8.10 PFIZER INC.

    8.10.1 COMPANY OVERVIEW

    8.10.2 FINANCIAL OVERVIEW

    8.10.3 BUSINESS STRATEGIES

         8.10.3.1 Investing in research and development

    8.10.4 PRODUCT PORTFOLIO

    8.10.5 RECENT DEVELOPMENTS

8.11 TAKEDA PHARMACEUTICAL

    8.11.1 COMPANY OVERVIEW

    8.11.2 FINANCIAL OVERVIEW

    8.11.3 BUSINESS STRATEGIES

         8.11.3.1 Investing in emerging economies

         8.11.3.2 Investing in research and development

    8.11.4 PRODUCT PORTFOLIO

    8.11.5 RECENT DEVELOPMENTS

8.12 VALEANT PHARMACEUTICALS

    8.12.1 COMPANY OVERVIEW

    8.12.2 FINANCIAL OVERVIEW

    8.12.3 BUSINESS STRATEGIES

         8.12.3.1 Strategic alliance

    8.12.4 PRODUCT PORTFOLIO

    8.12.5 RECENT DEVELOPMENTS

8.13 WATSON PHARMACEUTICALS, INC.

    8.13.1 COMPANY OVERVIEW

    8.13.2 FINANCIAL OVERVIEW

    8.13.3 BUSINESS STRATEGIES
           8.13.3.1 Investing in generic and biosimilar segments

           8.13.3.2 Investing in research and development

    8.13.4 PRODUCT PORTFOLIO

    8.13.5 RECENT DEVELOPMENTS



About Us:

Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.

Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States

Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

				
DOCUMENT INFO
Shared By:
Stats:
views:26
posted:1/18/2013
language:
pages:12
Description: This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate. This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report. Sourse:http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html